Spyre Therapeutics to Participate in Upcoming June Investor Conferences
Rhea-AI Summary
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on developing antibody treatments for Inflammatory Bowel Disease (IBD) and other immune-mediated diseases, has announced its participation in two major healthcare investor conferences in June 2025.
The company will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 8:10am ET, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 9:20am ET. Live webcasts and replays will be accessible through Spyre's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, SYRE gained 0.60%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Event: Jefferies Global Healthcare Conference
Date: Wednesday, June 4, 2025
Fireside Time: 8:10am ET
Event: Goldman Sachs 46th Annual Global Healthcare Conference 2025
Date: Monday, June 9, 2025
Fireside Time: 9:20am ET
Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.
About Spyre Therapeutics
Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.
Follow Spyre Therapeutics on social media: @spyretx and LinkedIn
View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-participate-in-upcoming-june-investor-conferences-302464699.html
SOURCE Spyre Therapeutics, Inc.
